U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809946) titled 'Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy' on Jan. 30.
Brief Summary: In this feasibility study, we combine bronchoscopy with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Study Start Date: June 01, 2025
Study Type: INTERVENTIONAL
Condition:
Lung Neoplasms
Pulmonary Neoplasms
Lymph Node Involvement
Intervention:
DRUG: injection with 15 mg bevacizumab-800CW before bronchoscopy
Patients will receive an intravenous administration of 15 mg bevacizumab-800CW be...